BIOMAT Database Logo BIOMAT Database Logo

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. 2010

Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA.

Of 529 patients with heart failure and a mean left ventricular ejection fraction of 29%, 209 (40%) were treated with cardiac resynchronization therapy (CRT) plus an implantable cardioverter-defibrillator (ICD) and 320 (60%) with an ICD. Mean follow-up was 34 months for both groups. Stepwise logistic regression analysis showed that significant independent variables for appropriate ICD shocks were statins (risk ratio = 0.35, P < .0001), smoking (risk ratio = 2.52, P < .0001), and digoxin (risk ratio = 1.92, P = .0001). Significant independent variables for time to deaths were use of CRT (risk ratio = 0.32, P = .0006), statins (risk ratio = 0.18, P < .0001), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (risk ratio = 0.10, P < .0001), hypertension (risk ratio = 24.15, P < .0001), diabetes (risk ratio = 2.54, P = .0005), and age (risk ratio = 1.06, P < .0001). In conclusion, statins reduced and smoking and digoxin increased appropriate ICD shocks. Use of CRT, statins, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers reduced mortality and hypertension, diabetes, and older age increased mortality.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator Therapy in Advanced Heart Failure.
July 2016, Heart failure clinics,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure.
May 2004, Current opinion in cardiology,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Prediction of appropriate defibrillator therapy in heart failure patients treated with cardiac resynchronization therapy.
January 2010, The American journal of cardiology,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review.
May 2021, Cost effectiveness and resource allocation : C/E,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Stroke after implantable cardioverter-defibrillator shocks in patients with heart failure.
January 2024, Kardiologia polska,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy.
August 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience.
December 2014, European journal of heart failure,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis.
November 2016, International journal of cardiology,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Diabetes Mellitus and Outcomes of Cardiac Resynchronization With Implantable Cardioverter-Defibrillator Therapy in Older Patients With Heart Failure.
August 2016, Circulation. Arrhythmia and electrophysiology,
Harit Desai, and Wilbert S Aronow, and Chul Ahn, and Fausan S Tsai, and Hoang M Lai, and Kaushang Gandhi, and Harshad Amin, and William H Frishman, and Kumar Kalapatapu, and Martin Cohen, and Carmine Sorbera
Cardiac resynchronization therapy with and without implantable cardioverter-defibrillator.
June 2009, Circulation journal : official journal of the Japanese Circulation Society,
Copied contents to your clipboard!